| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/26/2002 | WO2002074249A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | WO2002074246A2 Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |
| 09/26/2002 | WO2002074235A2 Heterocyclic compounds for therapeutic use |
| 09/26/2002 | WO2002074232A2 Antitumor compositions containing taxane derivatives |
| 09/26/2002 | WO2002074229A2 A combination comprising combretastatin and anticancer agents |
| 09/26/2002 | WO2002074193A2 METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
| 09/26/2002 | WO2002074158A2 Two-phase processing of thermosensitive polymers for use as biomaterials |
| 09/26/2002 | WO2002074048A2 P-glycoproteins and uses thereof |
| 09/26/2002 | WO2002074042A2 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 09/26/2002 | WO2002074034A2 Novel medicament compositions based on anticholinergic agents and endothelin antagonists |
| 09/26/2002 | WO2002060900A3 Antagonists of mcp-1 function and methods of use thereof |
| 09/26/2002 | WO2002055517A3 4-(hetero)aryl substituted indolinones |
| 09/26/2002 | WO2002055064A3 Mucopolysaccharidosis therapies |
| 09/26/2002 | WO2002040484A3 Novel imidazole derivatives, production method thereof and use thereof |
| 09/26/2002 | WO2002032397A8 Electroprocessing in drug delivery and cell encapsulation |
| 09/26/2002 | WO2002026954A3 Truncated phosphodiesterase-7 polypeptides |
| 09/26/2002 | WO2002022685A3 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 09/26/2002 | WO2002016611A3 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 09/26/2002 | WO2002015918A3 Method and compositions for promoting osteogenesis |
| 09/26/2002 | WO2002003975A3 Combinations of ssri and estrogenic agents |
| 09/26/2002 | WO2001098332A3 Secreted redox proteins |
| 09/26/2002 | WO2001098317A3 Alpha-glycosylceramides for treating bacterial and fungal infections |
| 09/26/2002 | WO2001095711A3 Transgenic mice containing nuclear hormone receptor gene disruptions |
| 09/26/2002 | WO2001090159B1 Compositions and methods for delivery of a molecule into a cell |
| 09/26/2002 | WO2001087343A3 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 09/26/2002 | WO2001083775A3 Proteases |
| 09/26/2002 | WO2001080837A2 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 09/26/2002 | WO2001074338A1 Transdermal therapeutic system for the delivery of lerisetron |
| 09/26/2002 | WO2001070206B1 Combination of lecithin with ascorbic acid |
| 09/26/2002 | WO2001051051B1 AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS |
| 09/26/2002 | WO2001034119A9 Inhibitors of crystallization in a solid dispersion |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001015744A9 Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| 09/26/2002 | WO2001011054A9 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS UDP-N-ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE (S. AUREUS MurB) |
| 09/26/2002 | WO2000074634A9 Methods and compositions for modulating cell proliferation and cell death |
| 09/26/2002 | US20020138865 In vitro transfection, storage and transfer of male germ cells for generation of transgenic species & genetic therapies |
| 09/26/2002 | US20020138862 Mice show an increased insulin sensitivity, and resistance to weight gain compared to wild-type mice on same diet; screening for enzyme inhibitors; antiobesity, antidiabetic agents |
| 09/26/2002 | US20020138860 Novel uses of mammalian CCR6 receptors and related reagents |
| 09/26/2002 | US20020137903 Sodium dependent glucose transporters found in the intestine and kidney (SGLT2); treating diabetes |
| 09/26/2002 | US20020137798 Treatment of disorders secondary to organic impairments |
| 09/26/2002 | US20020137797 Alpha-Difluoromethylornithine (DFMO) suppresses polyamine levels in the human prostate |
| 09/26/2002 | US20020137794 Use of rar antagonists as modulators of hormone mediated processes |
| 09/26/2002 | US20020137792 Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137777 Benzothiazole, riluzole, phenylbenzothiazole or lifarizine as blocking agents to limit sodium/calcium exchange in the retinal ganglion cells |
| 09/26/2002 | US20020137767 (+)-1-(1-(2-chlorophenyl)cyclopropyl)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline D1/D5 antagonist or partial agonist |
| 09/26/2002 | US20020137764 .0005-5 wt% of a tiotropium salt, an antiallergic, antihistamine, steroid, or leukotriene antagonist, water or water/ethanol mixture and a preservative; antiasthmatics and chronic obstructive pulmonary disease treatment |
| 09/26/2002 | US20020137761 Treating tolerance or drug addiction; analgesics |
| 09/26/2002 | US20020137755 Tyrosine kinase inhibitors |
| 09/26/2002 | US20020137749 Formulation for menopausal women |
| 09/26/2002 | US20020137748 Reducing intestinal toxicity of a noncompetitive thymidylate synthase inhibitor by co-administering a folate derivative without blocking therapy; anticancer, antitumore agents |
| 09/26/2002 | US20020137740 CRF (corticotropin releasing factor) antagonists; 4-(2-Chloro-4-methoxyphenyl)-5-methyl-2-(N-(5-ethoxy-carbonyl-2 -methoxyphenyl)-N-propylamino)thiazole for example |
| 09/26/2002 | US20020137732 Small molecule inhibitors targeted at Bcl-2 |
| 09/26/2002 | US20020137722 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| 09/26/2002 | US20020137716 Administering nucleotide sequence |
| 09/26/2002 | US20020137714 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 09/26/2002 | US20020137693 Comprising an admixture of a natural inhibitor of epidermal growth factor receptor (EGFR) activation or a derivative or analog and a dermatological carrier; antipeeling agents; genistein and other isoflavones and other plant extracts |
| 09/26/2002 | US20020137692 Treating and preventing hair loss, i.e., alopecia; using as opener, minoxidil, and as inhibitor, procyanidin B2; kits |
| 09/26/2002 | US20020137691 Supplement collagen and elastic tissues and thicken the dermis; administering a sugar compound converting mucopoly-saccharides; enzyme inhibitor of collangenase/elastase; an amino acid; fat burner, vaso-dilator and chromium picolinate |
| 09/26/2002 | US20020137690 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 09/26/2002 | US20020137689 Hypolipidemic agents |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137669 Treatment of dyskinesia |
| 09/26/2002 | US20020137666 Use of exendins and agonists thereof for the reduction of food intake |
| 09/26/2002 | US20020137663 The anti-neoplastic agent ET-743 inhibits trans activation by SXR |
| 09/26/2002 | US20020137205 Lipid uptake assays |
| 09/26/2002 | US20020137184 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137137 Genetic engineering; polypeptides |
| 09/26/2002 | US20020137129 Polypeptides; genetic engineering; drug development |
| 09/26/2002 | US20020137086 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| 09/26/2002 | US20020137049 Pablo, a polypeptide that interacts with Bcl-xL, and uses related thereto |
| 09/26/2002 | US20020137028 Use of neuronal apoptosis inhibitor protein (naip) |
| 09/26/2002 | US20020136786 Composition and method for smoke detoxification |
| 09/26/2002 | US20020136776 Poly( alpha -hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents |
| 09/26/2002 | US20020136769 Nanogel networks including polyion polymer fragments and biological agent compositions thereof |
| 09/26/2002 | US20020136766 Doxycycline administered in three dosages forms of different release profiles, with Cmax being reached in < twelve hours |
| 09/26/2002 | US20020136765 Fluroquinilone antibiotic product, use and formulation thereof |
| 09/26/2002 | US20020136764 Antibiotic product, use and formulation thereof |
| 09/26/2002 | US20020136763 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 09/26/2002 | US20020136729 Combined physical and immunotherapy for cancer |
| 09/26/2002 | US20020136726 Method for selectively delivering agent to arterial smooth muscle cells in mammal comprising administering agent and substance which selectively binds arterial smooth muscle cell-specific surface molecule selected from ephrin family |
| 09/26/2002 | US20020136724 Methods for treating rheumatoid arthritis using IL-17 antagonists |
| 09/26/2002 | US20020136720 Methods of using IMXP-888 and IMXP-888 antagonists |
| 09/26/2002 | US20020136717 Process for screening chemical compounds for modulating the interaction of an EVH1 domain or a protein having an EVH1 domain with an EVH1 binding domain or a protein having an EVH1 binding domain, and a process for detecting said interaction |
| 09/26/2002 | US20020136711 Compositions used in human treatment |
| 09/26/2002 | US20020135085 Production scale method of forming microparticles |
| 09/26/2002 | DE10113366A1 Medicament for treating inflammatory or obstructive respiratory diseases, e.g. asthma or chronic obstructive pulmonary disease, containing synergistic combination of anticholinergic agent and endothelin antagonist |
| 09/26/2002 | DE10112041A1 p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate p-thienylbenzyl amides as agonists of angiotensin- (1-7) receptors, processes for their preparation, their use and pharmaceutical compositions containing them |
| 09/26/2002 | CA2442717A1 Methods for restoring cognitive function following systemic stress |
| 09/26/2002 | CA2441425A1 Antipruritics |
| 09/26/2002 | CA2441291A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | CA2441162A1 Pharmaceutical composition comprising, as an active ingredient, triazaspiro[5.5]undecane derivative |
| 09/26/2002 | CA2441155A1 Methods of treating respiratory conditions |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441147A1 Methods of treating disorders of the eye and surrounding tissue with thymosin .beta.4 (t.beta.4), analogues, isoforms and other derivatives |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2441086A1 Identification of gene expression alterations underlying the aging process in mammals |
| 09/26/2002 | CA2440844A1 Two-phase processing of thermosensitive polymers for use as biomaterials |
| 09/26/2002 | CA2440687A1 Dermatological preparations |